vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
33.57
-0.34 (-1.00%)
At close: Aug 26, 2026, 4:00 PM EDT
33.95
+0.38 (1.13%)
After-hours: Aug 26, 2026, 7:30 PM EDT
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $36.84M in the twelve months ending June 30, 2026, up 216,600.00% year-over-year.
Revenue (ttm)
$36.84M
Revenue Growth
+216,600.00%
P/S Ratio
11.32
Revenue / Employee
$1,416,885
Employees
26
Market Cap
417.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | 2.76M | -9.67M | -77.77% |
| Dec 31, 2018 | 12.43M | 12.14M | 4,172.85% |
| Dec 31, 2017 | 291.00K | -343.00K | -54.10% |
| Dec 31, 2016 | 634.00K | 115.00K | 22.16% |
| Dec 31, 2015 | 519.00K | -1.03M | -66.49% |
| Dec 31, 2014 | 1.55M | 573.00K | 58.71% |
| Dec 31, 2013 | 976.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Foghorn Therapeutics | 36.74M |
| Arcturus Therapeutics Holdings | 29.37M |
| X4 Pharmaceuticals | 15.85M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
VTVT News
- 7 days ago - vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - vTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright - TheFly
- 20 days ago - vTv Therapeutics reports Q2 EPS ($1.05), consensus (99c) - TheFly
- 20 days ago - vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 20 days ago - vTv Therapeutics Quarterly report: Q2 2026 - Filings
- 20 days ago - vTv Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - vTv Therapeutics price target raised to $57 from $49 at BTIG - TheFly
- 2 months ago - vTv Therapeutics initiated with a Buy at Rodman & Renshaw - TheFly